Clinical Trial Results Confirm Amino Acid Based Medical Food Theramine® More Effective at Improving Chronic Back Pain than NSAID Pain Medications

Los Angeles, CA, September  23, 2014 — Targeted Medical Pharma, Inc. (OTCQB: TRGM) a drug discovery and development company, announced the results of a second, double-blind clinical trial which confirmed that Theramine was shown not only to be more effective than ibuprofen in reducing low back pain, but also demonstrated a significant reduction in measures of inflammation. In this 28 day, multi-center trial, subjects taking Theramine as either a standalone medication or in conjunction with a low dose ibuprofen, demonstrated a significant reduction in both Continue reading →

Targeted Medical Pharma to Present at Sachs Associated 14th Annual Biotech in Europe Forum for Global Partnering and Investment

Los Angeles, September 16, 2014 — Targeted Medical Pharma (OTCQB:TRGM), today announced that William Shell, M.D., Chairman, CSO and CEO  is scheduled to present the latest company information regarding the advances in therapeutic nutrition and medical foods technology, at the 14th Annual Biotech in Europe Forum at the Congress Center in Basel, Switzerland. The presentation is scheduled for September 30th, 2014 at 11:45 am in the Lima Room. Dr. Shell will also be a panelist in the discussion regarding advancements in Neuroscience at 3:30 pm. Additional information Continue reading →

Targeted Medical Pharma Reports Second Quarter 2014 Financial Results

Los Angeles, CA, August 14, 2014 – Targeted Medical Pharma, Inc. (OTCQB: TRGM), today announced financial results for its second quarter ended June 30, 2014.  The Company posted increased revenues, gross profit and an increase in net income before interest, taxes, depreciation and amortization, and stock based compensation (Adjusted EBITDA*) on a quarter-over-quarter basis. Financial Overview Quarter-over-Quarter Comparison: Financial results for the three months ended June 30, 2014 compared to the three months ended June 30, 2013 Total revenue of $2.2 million, a 16% improvement Continue reading →

Targeted Medical Pharma to Sponsor Clinical Trial Conducted by U.S. Army and Henry M. Jackson Foundation

Study to Examine the Use of Theramine for the Treatment of Acute or Sub-Acute Lower Back Pain due to Injury Los Angeles, CA, July 28, 2014 — Targeted Medical Pharma, Inc. (OTCQB: TRGM), today announced the completion of an agreement to sponsor an investigator-initiated study with the United States Army and The Henry M. Jackson Foundation for the Advancement of Military Medicine Inc. (HJF). The study, which is slated to start enrolling patients in Q2 of 2014, will involve the Company’s medical food Theramine. The Continue reading →

Targeted Medical Pharma Appoints Two New Independent Members to the Board of Directors

 Health Care Veteran Kerry Weems and Corporate Finance Expert Paul Pelosi, Jr. Join the Advisory Team Los Angeles, CA, June 13, 2014 — Targeted Medical Pharma, Inc. (OTCQB: TRGM), today announced the addition of two independent members to the Company’s board of directors. The Company welcomes back health care specialist Kerry Weems to the board as an independent director and chairman of the Nominating and Governance Committee, as well as corporate finance expert Paul Pelosi, Jr. as an independent director. A nationally respected expert in Continue reading →

Targeted Medical Pharma to Present at the Third Annual Marcum MicroCap Conference

Los Angeles, CA –  May 23, 2014 – Targeted Medical Pharma (OTCQB: TRGM), a leader in the medical food manufacturing sector, announced today that it will be a featured presenter at the 3rd Annual Marcum MicroCap Conference on Thursday, May 29, 2014 in New York City at the Grand Hyatt Hotel. The Company’s presentation by William Shell M.D., Chief Executive Officer and Chief Science Officer, is scheduled to begin at 11:30 a.m. ET. The annual Marcum MicroCap Conference is a signature showcase for superior quality, Continue reading →

Targeted Medical Pharma Looks to China as the Next Medical Food Market

Company discusses distribution of medical foods with large Chinese pharmaceutical company  Los Angeles, May 20, 2014 – Targeted Medical Pharma (OTCQB: TRGM), is currently discussing the logistics of importing the Company’s medical food products into China, with a large Chinese pharmaceutical company. No assurances can be made that a definitive agreement will be consummated between the two Companies at this time. “Growth of international sales and distribution will contribute to the success of our 2014 fiscal initiatives,” said William Shell, M.D. Chief Executive Officer and Continue reading →

Targeted Medical Pharma Reports First Quarter 2014 Financial Results

Los Angeles, CA, May 21, 2014 — Targeted Medical Pharma, Inc. (OTCQB: TRGM), a biotechnology company that develops and markets medical foods for the treatment of chronic disease, including pain syndromes, peripheral neuropathy, hypertension, obesity, sleep and cognitive disorders announced financial results for its first quarter ended March 31, 2014. William Shell, M.D., Chief Executive Officer and Chief Science Officer of Targeted Medical Pharma stated, “During the remainder of 2014 we will continue to focus on the expansion of sales and marketing efforts to increase Continue reading →

Targeted Medical Pharma Completes Middle East Distribution Agreement

Creates new market opportunity for increased product sales  Los Angeles, April 28,  2014 – Targeted Medical Pharma (OTCQB: TRGM),  announced the completion of an agreement between Analytical Testing Laboratories (ATL), a Lebanon based company that specializes in drug testing services and inborn errors of metabolism,  for the exclusive distribution of the company’s amino acid based products to physicians and pharmacies throughout the Middle East. The Agreement provides ATL with a limited exclusive license for the marketing and sales of certain products in twenty countries in Continue reading →

Targeted Medical Pharma Reports Fourth Quarter and Fiscal Year 2013 Financial Results

Year-Over-Year Revenue Increase of 31% and Gross Profit Increase of 60% for the year ended December 31, 2013 Los Angeles, CA, March 31, 2014 — Targeted Medical Pharma, Inc. (OTCQB: TRGM), today announced financial results for its fourth quarter and fiscal year ended December 31, 2013.  The Company posted increased revenues, gross profit and a reduction in net loss before interest, taxes, depreciation and amortization, stock based compensation (Adjusted EBITDA*) on both a year-over-year and a quarterly basis. Financial Overview Year-over-Year Comparison: Improved financial results Continue reading →